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Hospital Consumer Assessment of Healthcare Providers and
Systems (HCAHPS) is a standardized survey for measuring
patients’ perception of their hospital experience. It is intended
to improve quality of care, allow comparison of hospitals on
topics that are important to consumers and enhance
accountability in healthcare by increasing transparency of the
quality of hospital care. HCAHPS has been a primary focus of
our hospital in assessing quality of care at the BMT unit.
HCAHPS surveys were mailed to a random sample of BMT pa-
tients48hours to4weekspostdischarge fromtheunit. Surveys
returned between May 2012 and September 2012 (group A,
n¼25)were reviewed (table 2). HCAHPS scoreswere below the
required target of 75% in all areas. A quality improvement plan
(table1)was implemented tohelp improveHCAHPS scores and
targeted physician communication, nursing communication,
pain management and discharge planning.Table 1
Hospital Consumer Assessment of Healthcare Providers and Systems
Improvement Plan
1-Nursewill be present in the patient’s room during daily physician visit
2-Physicians will try to sit down during communicationwith the patient
and always ask patient if all concerns were adequately addressed at
the end of each visit.
3-Nurses will perform hourly rounds on patients.
4-Patients’ pain will be assessed on a daily basis through joined
physician/nursing round
5-Discharge process:
-instructions about diet, activity and follow up provided by physician or
midlevel
-written discharge instructions provided by nrse
-Discharge medications ﬁlled by BMT pharmacist who discusses the
medications with patient and caregiver, ﬁlls the pill box and provides
written instruction for indications, schedule and side effects.
-Physician or midlevel will review discharge instruction andmedication
list within 48 hours of discharge in the outpatient setting.
-Outpatient clinic nurse will follow up on line care and supplies.
Table 2
HCAHPS scores before (group A) and after (group B) implementing quality
improvement Plan
HCAHPS Measures Group A (n¼25) Group B (n¼19)
Top box Percentile
among
hospital units
Top
box
Percentile
among
hospital units
Recommend Hospital 64 63% 95 99%
Communication with
Nurses
72 29% 100 99%
Response of hospital
staff
36 1% 83 97%
Communication with
Doctors
81 54% 95 99%
Pain Management 69 39% 95 99%
Discahrge
information
92 75% 100 99%After implementing the HCAHPS improvement plan, 19 pa-
tient surveys (group B) were returned from October till April
2013.The satisfaction scores were all above the 90th percen-
tile reﬂecting a signiﬁcant improvement in patient experi-
ence.Our Data shows that HCAHPS scores can be signiﬁcantly
improved through a cohesive plan based on close commu-
nication between all team members and assessing patient
needs on a more frequent basis.169
Quality Improvement: Decreasing Length of Stay and
Readmission Rates for Bone Marrow Transplant Patients
Jason Scott Starr, Erin Mobley, Vivek Roy, John Wade,
Virginia Lesperance. Bone Marrow Transplant, Mayo Clinic,
Jacksonville, FL
Weused the Plan-Do-Study-Act (PDSA) quality improvement
methodology to decrease the average length of stay (ALOS)
and readmission rates within 30 days for bone marrow
transplant patients
June 1, 2011 through November 15, 2012 was chosen for
baseline data (pre-implementation). Changes in workﬂows,
per PDSAmethodology, were implemented on November 16,
2012 including: a streamlined admission process, pre-
transplant education in the outpatient rather than inpatient
setting, improved anti-emetic strategy, and a consistent,
protocol driven TPN use and taper.
We studied the effects to these changes through August 31,
2013 (post-implementation). We also reviewed patient
satisfaction surveys during the same intervals.
The proportion of autologous to allogeneic transplants pre-
and post-implementation was similar pre- and post- imple-
mentation (72% and 75% autologous). The ALOS (95% CI) for
autologous transplant patients decreased from 21.03 (19.66
e 22.40; n ¼ 72) to 18.54 days (17.63 e 19.46; n ¼ 59). ALOS
for allogeneic patients decreased from 33.63 (29.61 e 37.62;
n ¼ 28) to 26.05 (23.56 e 28.55; n ¼ 19).
The overall 30-day readmission rate decreased from 6% to
2.56%; autologous from 1.39% to 1.69%, while allogeneic
decreased from 17.69% to 5.26%. TPN utilization decreased
from 60.00% to 39.74%, and the average number of days on
TPN was 11.43 and 8.42, respectively.
Overall, the Patient Satisfaction Index (PSI) increased from
90.36% to 93.57%. Improvements were noted in the following
domains: pre-BMT education, BMT inpatient care, discharge
and teaching materials, and transition to referring physician.
Discussion: The implementation of these changes led to a
decrease in ALOS, readmission rates TPN use, and an increase
in patient satisfaction.
These changes have important implications. Reduced LOS
is economically desirable, reduces infection risk and is liked
by patients. Similarly, less TPN use reduces risk of compli-
cations such as infection and hepatic dysfunction.
Our experience illustrates the ability of PDSA methodol-
ogy to make a quick change that can have signiﬁcant impact,
in a relatively short amount of time.170
Standardization of IV Line Set-up to Improve Clinical
Outcomes
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Objective/Purpose: In August 2011, Fairview implemented
the new smart pump known as the Baxter Sigma. The
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the Omni pump, which was a multi chamber pump capable of
running four medications at one time and had unique tubing.
The Omni was able to run syringe medications as well as
medications in bags. The implementation forced Nursing
Practice Council (NPC) to brainstorm a line and pump set-up
thatwould provide an equivalent process andworkﬂowas the
Omni. Unfortunately, the Sigma can only run one bag medi-
cation at a time and does not have the capability to run a
syringe medication. The new set-up would require four Sigma
pumps and two syringe pumps to replace the one Omni.
METHOD: Two months prior to implementation, NPC
created a poster displaying a line set-up that could accom-
modate the needs to administer multiple IV medications
simultaneously per patient into a double lumen Hickman. In
addition, NPC implemented a standardized pump set-up to
supplement the line set-up by creating an “BMT Amplatz
pole” order where every patient admitted receives the
pumps pre set-up from supply chain. Monthly audits were
done to check staff compliance and were reported in a
monthly unit newsletter. Yearly competencies are used to
evaluation assimilation of knowledge. A survey will be con-
ducted showing staff satisfaction.
RESULTS: Since implementation of the standard line and
pump set-up, our cyclosporine line contamination has been
zero, which is a decrease. Based on ICAREs, Our medication
errors related to infusion in the wrong lumen and in-
compatibilities with other medications has decreased from 12
in 2011, eight in 2012 and two in 2013 to date. We continue to
have low BSI rates that are below the nation average. From
informal verbal surveys, we have heard an increase in staff
satisfaction related to productivity and time management.
CONCLUSION: Based on the results, we know that the stan-
dardization has decreased medication errors and increased
staff satisfaction. We continue to evaluate the effectiveness
of the standardization set-up and continue to look for ways
to improve patient care and safety.
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Figure 1. Ranked hospital-mean autologous HCT costs (n ¼ 32) and allogeneic HCT
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Transplant centers vary in their practices for evaluation,
treatment, and follow-up for patients receiving hematopoi-
etic cell transplantation (HCT). This variation among centers
has the potential to cause variation in costs of HCT. To
characterize differences in costs of autologous (auto) and
allogeneic (allo) HCT by hospital, we conducted a retro-
spective cohort study using the Nationwide Inpatient Sample
(NIS). The NIS captures hospital utilization and costs, on a
stratiﬁed sample of US hospitals. ICD9 diagnosis and proce-
dure codes were used to identify hospitalizations for HCT
from 2008-2010. Costs were measured by applying a cost-to-
charge ratio, were discounted to 2008 dollars and log-
transformed due to high skewedness. Analyses were
restricted to hospitals that performed  30 HCT/year for
patients  18 years, and stratiﬁed by transplant type. Our
ﬁnal cohort included 32 hospitals that performed allo HCT
(1,932 patients) and 22 hospitals that performed auto HCT
(3,164 patients). Linear regression was performed to assess
associations between costs and characteristics of patients
(age, gender, race, payer type, diagnosis and Elixhauser co-
morbidity index) and hospitals (hospital volume, ownership,
and teaching status). Adjusting for these characteristics did
not change the rank ordering of hospitals, and differences in
cost remained signiﬁcant (p<0.001). Overall, adjusted mean
cost among hospitals performing auto HCT was $47,990 and
costs varied by a factor of three. Among hospitals performing
allo HCT, adjusted mean cost was $86,580 with costs that
varied by a factor of ﬁve (Figure 1). A limitation of the NIS is
that data only includes initial HCT hospitalizations; hence,
we could not account for costs associated with outpatient
care and subsequent hospitalizations. In conclusion, we
found signiﬁcant variation in costs of HCT independent of
patient demographics and case mix. Future research should
investigate factors that inﬂuence cost variation and whether
uniform practice standards reduce costs of HCT.costs (n ¼ 24), 2008 e 2010. Hospital geometric means are shown with 95%
tal’s total volume of HCT cases. Hospitals in the highest and lowest quintile are
